Twiss, James
Whalley, Diane
Doward, Lynda
Balp, Maria-Magdalena
Brass, Clifford A.
Cryer, Donna
Sanyal, Arun
Anstee, Quentin M.
Funding for this research was provided by:
Novartis
Article History
Received: 15 November 2022
Accepted: 4 May 2023
First Online: 14 July 2023
Declarations
:
: The FLIGHT-FXR study was approved by appropriate Institutional Review Boards at each center and all participants provided written consent. The RTI Institutional Review Board (Federalwide Assurance Number 3331) determined the use of anonymized trial data for the purpose of the post hoc psychometric analysis did not require separate Institutional Review Board approval or oversight.
: Not applicable.
: This study was completed under a research contract between RTI Health Solutions and Novartis Pharma AG and was funded by Novartis Pharma AG. JT, DW, and LD are salaried employees of RTI Health Solutions. MMB is a salaried employee of Novartis. CAB was a salaried employee of Novartis at the time the study was conducted. DC is a salaried employee of the Global Liver Institute, which received consulting fees from Novartis in support of this research. AS has received research grants and consulting fees from Novartis. QMA has received research grants and consulting fees from Novartis and is participating in research collaborations with Novartis.